Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulations

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 384-393

  Li, Yongmei ^a   Zhou, Jin ^a   Ramsden, Diane ^a   Taub, Mitchell E ^a   O'Brien, Drané ^a   Xu, Jun ^a   Busacca, Carl A ^a   Gonnella, Nina ^a   Tweedie, Donald J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG STABILITY; DRUG STORAGE; FECES; FEMALE; HEPATOCYTES; HUMANS; INTESTINAL ABSORPTION; INTESTINES; KINETICS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES; OLIGOPEPTIDES; PROTEIN BINDING; THIAZOLES;

EID: 84893823809     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055863     Document Type: Article

References (47)

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, and Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
2. Chen LZ, Rose P, Mao Y, Yong CL, St. George R, Huang F, Latli B, Mandarino D, and Li Y (2014) Steady-state disposition of the hepatitis C NS3/NS4 protease inhibitor faldaprevir in healthy male subjects. Antimicrob Agents Chemother, in press.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
4. Duan J, Yong CL, Garneau M, Amad M, Bolger G, De Marte J, Montpetit H, Otis F, Jutras M, and Rhéaume M, et al. (2012) Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Xenobiotica 42:164-172.
5. European Medicines Agency (2012) Committee for Human Medicinal Products (CHMP): Guideline on the Investigation of Drug Interactions. [http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/ 2012/07/WC500129606.pdf (Accessed on Dec. 16, 2013)] EMA, London.
6. Food and Drug Administration (2012) Draft Guidance for Industry: Drug Interaction Studies: Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (Accessed on Dec. 16, 2013)] FDA, Silver Spring, MD.
7. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
8. Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633-1642.
9. Gonzalez SA (2010) Management of recurrent hepatitis C following liver transplantation. Gastroenterol Hepatol (NY) 6:637-645.
10. Hjelle JJ and Klaassen CD (1984) Glucuronidation and biliary excretion of acetaminophen in rats. J Pharmacol Exp Ther 228:407-413.
11. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
12. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, and Kato M, , et al. (2002) Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:E25.
13. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
14. Kiser JJ, Burton JR, Jr, and Everson GT (2013) Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 10:596-606.
15. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
16. Li Y, Xu J, Lai WG, Whitcher-Johnstone A, and Tweedie DJ (2012) Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase. Drug Metab Dispos 40:1130-1137.
17. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
18. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, and Sugiyama Y (2006) Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
19. Nedderman AN, Dear GJ, North S, Obach RS, and Higton D (2011) From definition to implementation: a cross-industry perspective of past, current and future MIST strategies. Xenobiotica 41:605-622.
20. Obach RS, Nedderman AN, and Smith DA (2012) Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42:46-56.
21. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
22. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
23. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, and Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538.
24. Poulin P, Hop CE, Ho Q, Halladay JS, Haddad S, and Kenny JR (2012a) Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101:4308-4326.
25. Poulin P, Kenny JR, Hop CE, and Haddad S (2012b) In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 101:838-851.
26. Ramsden D, Tweedie DJ, St George R, Chen LZ, and Li Y (2014a) Generating an IVIVC for metabolism and liver enrichment of an HCV drug, faldaprevir, using a rat hepatocyte model (HepatoPacTM). Drug Metab Dispos 42:407-414.
27. Ramsden D, Tweedie DJ, Chan TS, Taub ME, and Li Y (2014b) Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel co-cultured human hepatocyte system, HepatoPacTM. Drug Metab Dispos 42:394-406.
28. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Technol 1:441-448.
29. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
30. Scott EE and Halpert JR (2005) Structures of cytochrome P450 3A4. Trends Biochem Sci 30:5-7.
31. Sfakianos J, Coward L, Kirk M, and Barnes S (1997) Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J Nutr 127:1260-1268.
32. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
33. Shitara Y, Sato H, and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
34. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
35. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, and Datsenko Y, et al. (2013a) Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 57:2143-2154.
36. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, and Datsenko Y, et al. (2013b) Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57:2155-2163.
37. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3Amediated metabolism. Clin Pharmacol Ther 59:491-502.
38. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
39. Webborn PJ, Parker AJ, Denton RL, and Riley RJ (2007) In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 37: 1090-1109.
40. White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, and Thibeault D, et al. (2010) Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 54:4611-4618.
41. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
42. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, and Watkins PB (2000) The human CYP3A subfamily: practical considerations. Drug Metab Rev 32:339-361.
43. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, and Tucker GT (2007a) Misuse of the wellstirred model of hepatic drug clearance. Drug Metab Dispos 35:501-502.
44. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007b) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
45. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094.
46. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KL (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447-486.
47. Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, and Furr NA, et al. (2013) Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos 41:714-726.